Operator-Led M&A Advisory and Capital Raise Strategy
Biopharma M&A spend nearly doubled in 2025, with nine acquisitions exceeding USD 10 billion - the highest concentration of mega-deals on record according to IQVIA. ING forecasts continued acceleration in 2026, driven by a USD 200–400 billion patent cliff that is forcing large acquirers including AbbVie, Roche, Pfizer, and Merck to replace revenue at scale. Merck alone faces USD 18 billion in patent-driven revenue losses over the next five years - a pressure so acute it nearly drove a USD 30 billion acquisition of Revolution Medicines in January 2026.
Yet despite record deal volume, 50–70% of biopharma acquisitions fail to create the value projected at signing. The most common cause is not bad science or wrong pricing - it is the gap between strategic intent and operational execution. Integration is where deals are won or lost, and most companies treat it as a post-close project rather than a pre-close strategy.
Katogen's M&A advisory practice is grounded in experience from 17 completed acquisitions and USD 4 billion+ raised across the biopharma sector - including cross-border transactions across North America, Europe, and Asia. We have been on both sides of the table - as acquirer, as acquired, and as the operator responsible for making the deal work after close. That experience is the foundation of everything we do.
Photo by ThisisEngineering on Unsplash
What We Do
Deal Thesis Development
Before a transaction begins, we help you answer the most important question: why does this deal make strategic sense, and what does success look like 18 months post-close? A clear, defensible deal thesis is the foundation of every value-creating acquisition.
Capital Raise Strategy
We have raised USD 4B+ across multiple biopharma builds and turnarounds. We know what sophisticated institutional investors and strategic partners look for — and we help leadership teams build the financial narrative, investor materials, and capital strategy to attract the right capital at the right terms.
Acquirer Mapping and Target Identification
We help growth-stage companies map their likely acquirer landscape — understanding who will want to buy them, why, and at what strategic premium — so they can proactively position for the right conversation rather than react to inbound interest.
Transaction Preparation and Diligence Support
We prepare companies for the diligence process — identifying and addressing the issues a sophisticated acquirer will find before they find them. Clean CMC, credible supply chain, defensible reimbursement strategy, strong organizational narrative. We build the story and fix the gaps.
Integration Planning and Execution
Most biopharma deals fail not in the negotiation but in the integration. We help acquiring companies build integration plans that begin during diligence — not after close — covering talent retention, organizational design, regulatory alignment, and commercial execution.
Built for the Operator's Seat
Who this is for
CEOs, CFOs, and business development leaders preparing for acquisitions, divestitures, licensing transactions, or capital raises — and boards that need operator-grade diligence and integration planning before signing.
Why Katogen
Katogen brings 17 completed acquisitions and USD 4B+ raised from the acquirer, seller, and post-close operator seat — not a transaction template. Recommendations reflect how deals actually close, integrate, and create value.
See the full biopharma consulting overview for all practice areas.
WORK WITH KATOGEN
If you are navigating a strategic inflection point — a capital raise, an acquisition, a turnaround, a regulatory challenge, or simply a moment where you need an experienced operator in your corner — we would welcome the conversation. Engagements are selective. The first step is a direct conversation to understand your situation and determine where Katogen can add the most value.
